Skip to main content
Top
Published in:

01-12-2025 | Spondyloarthropathy | Review

Axial Spondyloarthritis Clinical Research Year in Review: SPARTAN 2024 Annual Meeting Proceedings

Author: Mohamad Bittar

Published in: Current Rheumatology Reports | Issue 1/2025

Login to get access

Abstract

Purpose of Review

The purpose of this review is to highlight high impact clinical research in axial spondyloarthritis that was published between May 2023 and April 2024. These publications were presented at the SPARTAN annual meeting in May 2024.

Recent Findings

Three publications addressed the rate and predictors of radiographic progression in axial spondyloarthritis. MRI-based synthetic CT was introduced as a new modality to assess spinal structural damage. One of the first definitions of difficult to treat axial spondyloarthritis was published. Biologic taper, flare rates, and predictors of flares were discussed. Minimally invasive one-level osteotomy can be an option to correct kyphosis with less risk compared to standard approach. Different therapeutic classes seem to be protective against anterior uveitis in axial spondyloarthritis. Patients who receive biologic or targeted synthetic disease modifying antirheumatic drugs are at increased risk of non-serious infections, but not serious infections that are associated with hospitalization or mortality.

Summary

This year-in-review session covered different concepts, including imaging and radiographic progression, difficult to treat axial spondyloarthritis, biologic taper, surgery, anterior uveitis, and risk of infections.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Axial Spondyloarthritis Clinical Research Year in Review: SPARTAN 2024 Annual Meeting Proceedings
Author
Mohamad Bittar
Publication date
01-12-2025
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 1/2025
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-024-01178-1

Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.

Supported by: Abbott Diabetes Care

Watch the full video

Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.

Supported by: Abbott Diabetes Care

Log in / Register to watch the full video

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025: the 85th Scientific Sessions

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s annual meeting.

Read more